← Back to headlines
Citi Initiates Neutral Rating for BridgeBio
Citi has begun its coverage of BridgeBio with a neutral rating, expressing caution about the company's cardiomyopathy story as a guaranteed success.
19 May, 16:15 — 19 May, 16:15
Sources
Showing 1 of 1 sources
Related Stories
South Korea Central Bank Raises Rates to 3 Percent Amid Inflation Concerns
14m ago
Meta Agrees to $17 Billion Settlement Over Teen Mental Health Lawsuits
32m ago
Nvidia in Talks to Acquire AI Platform Hugging Face for Over $13 Billion
41m ago
Mesoblast Reports Strong Revenue Growth Amid Commercial Transition
55m ago